MAMohammed Abusafia

Mohammed Abusafia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammed Abusafia has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GLP-1 Analogues and Long-Term Outcomes in Adults With Obesity and Elevated CRP: A Real-World Matched Cohort Study

    by Stuti Shah, Mohammed Abusafia, Hesham Sheashaa, Shada Jadam, Susan Ospina, David Kaelber, Susan K. Keen, Leslie Cho, Milind Y. Desai

  • Incremental prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy in a large contemporary cohort

    by Susan K Keen, Stuti Shah, Hesham Sheashaa, Mohammed Abusafia, Shada Jadam, Simrat Kaur, Andrew Gaballa, Susan Ospina, Katy Rutkowski, Jay Ramchand, et al.

    Aims: Extensive late gadolinium enhancement (LGE) is recognized in contemporary hypertrophic cardiomyopathy (HCM) risk assessment, but the prognostic value of lower quantitative thresholds remains debated. We aimed to evaluate whether quantitative LGE provides independent and incremental prognostic information beyond established clinical and phenotypic risk markers. Methods and results: This large contemporary cohort included 3035 patients (median age 58 years, 57% men); 56% had LGE, including 242 (8%) with LGE > 10%. Most patients have obstructive hypertrophic cardiomyopathy (71%), 1498 (69%) of which subsequently underwent septal reduction therapy at a median of 43 days [interquartile range (IQR) 5–107) from the cardiac magnetic resonance (CMR) date (1485 myectomies and 13 alcohol septal ablations). Over a median of 8.8 years, 331 (11%) primary endpoints occurred [295 cardiovascular deaths (9.7%) and 36 appropriate implantable cardioverter–defibrillator discharges (1.3%)]. On multivariable Cox proportional hazards analysis [adjusted for standard clinical and CMR variables, higher %LGE (1.05 per 1% increase, 95% confidence interval 1.03–1.06; P < 0.001)] was associated with primary events. Compared with no LGE, LGE ≥10% was associated with higher risk of the composite endpoint. Conclusion: In this large contemporary HCM cohort, quantitative LGE was independently associated with long-term adverse outcomes. LGE ≥10% identified patients at significantly higher risk, and incorporation of LGE improved discrimination beyond ESC and AHA/ACC risk assessment.

  • Open Access

    Sex‐Based Differences in Long‐Term Outcomes of Patients With Ascending Aortic Dilation

    by Mohammed Abusafia, Shada Jadam, Vidyasagar Kalahasti, Lifu Deng, Susan Ospina, Sana Sultana, Andrew Gaballa, Patrick Vargo, Xiaoying Lou, Eric E. Roselli, et al.

    Background: Thoracic ascending aortopathy (AA) is often asymptomatic and incidentally diagnosed, with surgical replacement recommended once it becomes aneurysmal. We report sex‐based characteristics and long‐term outcomes of patients with AA. Methods: This study analyzed 14 244 patients (21.1% women) with unrepaired AA (≥4 cm) diagnosed via echocardiography from 2010 to 2023, excluding those with acute aortic dissection/rupture at presentation (n=1179). Baseline data, including height‐indexed measurements (ascending aortic area height index and cross‐sectional area to height ratio), were collected. AA surgery and rates of aortic dissection/rupture during follow‐up were recorded. Cox proportional hazards and Kaplan–Meier survival analysis were performed for all‐cause mortality. Results: Women were older (63.6 versus 62.3 years) and had fewer comorbidities, including hypertension, diabetes, coronary artery disease, and dyslipidemia (all P 2 /m, both P P =0.04). At 0.86 years, 26.1% underwent surgery, with higher rates in women (28.2% versus 25.6%, P =0.002) and low in‐hospital mortality (0.9%). Over 6.2 years, women had worse survival (14.2% versus 11.2%, log‐rank P P P <0.001). Among unoperated patients (n=10 523), 62.9% of deaths and 72.4% of dissections/ruptures occurred in women with aortic diameters <5 cm. Conclusions: Despite fewer comorbidities and higher surgical rates, women with AA had worse long‐term survival. Sex‐specific thresholds for AA surgery may warrant consideration.


  • Open Access

    Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification

    by Milind Y. Desai, Andrew Gaballa, Yuichiro Okushi, Mohammed Abusafia, Shada Jadam, Katy Rutkowski, Susan Ospina, Sanaa Sultana, Maran Thamilarasan, Craig Asher, et al.

    Background: Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy treated at a multihospital referral center. Methods: We included 244 patients with obstructive hypertrophic cardiomyopathy (mean age, 64 years; 57% women, 21% with atrial fibrillation, 51% New York Heart Association class III, 82% on β‐blockers) treated with mavacamten for ≥3 months (171 for ≥12 months). Serial clinical and echocardiographic assessments were performed. Results: New York Heart Association class distribution improved over time: at 3 months 21% class I, 61% class II, and 18% class III; at 12 months 36% class I, 57% class II, and 8% class III. After a mean of 1.02 years, significant improvements were observed in resting and post‐Valsalva left ventricular outflow tract gradients (−31±33 and −57±46 mm Hg), interventricular septal thickness (−1.7±4 mm), left ventricular mass index (−9.5±32 g/m 2 ), left atrial volume index (−12±13 mL/m 2 ), E/e′ (−5.5±6.4), left ventricular global longitudinal strain (1.04%±3.1%), and various left atrial and right ventricular strain measures (all P <0.05). Temporary interruption occurred in 8 patients (3.2%), and 3 (1.2%) discontinued mavacamten permanently. There were 2 noncardiac deaths, 7 heart failure admissions, 14 cases of new‐onset atrial fibrillation, and 1 patient required septal reduction therapy. At the last visit, most patients were on 5 mg (49%) or 10 mg (26%) mavacamten. Conclusions: In this real‐world cohort, mavacamten treatment was associated with sustained symptomatic and echocardiographic improvements, suggesting a favorable disease‐modifying impact with minimal need for septal reduction therapy.